Decentralized clinical trials (DCTs) have been gaining interest throughout the past decade, but it wasn’t until the pandemic made them a necessity that their full potential for the life sciences industry began to be unlocked.
Due to travel restrictions, decreased availability of hospital resources, and social distancing requirements, DCTs emerged as a potential solution to ensure the continuity of ongoing trials.
Now, even years later, DCTs remain at the forefront of R&D modernization—the 2026 decentralized clinical trials market size is estimated at $10.74 billion and is projected to reach $21.06 billion by 2031, showing a CAGR of 14.42%.
Let’s take a deeper look at DCTs, including their benefits, challenges, and integration tips.
READ NEXT: 10 Amazing Ways AI is Revolutionizing Life Sciences Right Now
What are Decentralized Clinical Trials?
DCTs are a method of bringing the trial to the patient, instead of the reverse approach seen in traditional clinical trials. Decentralized trials can follow a fully virtual or hybrid model.
In a virtual model, clinical trials are conducted entirely off-site using digital health technologies (DHTs) such as telehealth, remote monitoring, eConsent, and electronic patient reported outcomes.
In the more commonly used hybrid model, clinical trials blend the traditional and virtual approaches. This approach offers a combination of remote data collection through digital health technologies, as well as clinical site visits or home visits for protocols that require in-person contact.
Although DCTs may not be suitable for all trial designs, many clinical trials can benefit from virtualizing one or more of their components.
Why There’s Been a Growing Shift Toward DCTs
In the years since Covid, decentralized clinical trials have seen rapid progression. Several factors have contributed to broader adoption:
- Pandemic‑driven necessity: Early-decade lockdowns and site closures forced sponsors to explore remote alternatives, demonstrating feasibility at scale.
- Regulatory alignment: Global agencies—particularly the FDA and EMA—are actively establishing guidance to support safe and compliant decentralized methodologies.
- Digital health maturity: Wearables, remote sensors, digital twins, and EHR integration now support real‑time data capture and continuous monitoring for enhanced data accuracy.
- Demand for diversity and access: DCTs reduce geographic and socioeconomic barriers, enabling participation from broader patient populations without requiring intensive travel.
Benefits of Decentralized Clinical Trials
A decentralized approach offers a wide range of benefits for both the trial patients and the researchers. Here are some common advantages seen with DCTs.
Reducing the Burden of Participation
Traditional trials often demand frequent site visits, long commutes, and rigid schedules—factors that disproportionately strain older, rural, and mobility‑restricted populations. DCTs directly address this by bringing trial activities to the participants.
Digital health technologies enable patients to engage from home, which lowers the risk of attrition and expands recruitment reach. Decentralized clinical trials were seen to have a retention rate of 89% compared to 60% in traditional trials, as well as a 300% greater rate of enrollment.
Improvements in Data Quantity and Quality
Continuous remote monitoring allows for real-time data collection as well as a reduction in patient subjectivity and data entry errors. This means that not only is a higher volume of data able to be collected, but that the data itself is more accurateand comprehensive than data collected on-site during traditional trial approaches.
Additionally, the collected data in DCTs is often comprised of a more diverse patient demographic since many barriers to trial entry have been removed. With greater participation among underrepresented and marginalized groups, data from DCTs shows a more accurate snapshot of how treatments perform across real‑world populations.
As a result, researchers gain evidence that reflects the full spectrum of patients who may eventually receive the therapy, strengthening both the scientific validity and practical relevance of study outcomes.
Trial Timeline Acceleration
A decentralized approach can streamline trial timelines, with research showing that DCTs can compress start-up cycles by 6-12 weeks compared to traditional trials. Flexible scheduling, remote assessment windows, and fewer site‑visit dependencies help studies progress more smoothly.
By leveraging remote monitoring, eConsent, and telemedicine, DCTs reduce patient recruitment time, accelerate data collection, and improve retention, often saving 3-6 months on trials.
Cost Reduction
DCTs can reduce costs associated with physical sites, such as site overhead, investigator meeting expenses, participant travel reimbursement, and facility‑based monitoring costs.
Even partial decentralization can replace higher‑cost in‑clinic procedures in specific areas. Telehealth and local partnerships can reduce certain site‑related costs while preserving data quality.
Challenges That Can Arise with Decentralized Clinical Trials
Although DCTs are a promising push toward the future, there are still a few hurdles to be aware of:
- Data integrity and validation: With distributed data sources, sponsors must ensure calibration, interoperability, and secure data flows across devices and platforms.
- Regulatory disparities: The U.S., EU, and Asian markets differ in digital health and telemedicine regulations, which can complicate global studies and slow implementation.
- Operational complexity: Coordinating decentralized activities, ensuring proper oversight of local healthcare providers, and maintaining GCP compliance demand comprehensive processes and vendor governance.
- Digital equity concerns: Broadband access, device literacy, and socioeconomic disparities may limit participation if not proactively addressed.
By keeping these obstacles top of mind, you can implement decentralized clinical trials as smoothly as possible and avoid potential hiccups.
How to Integrate DCTs in Your R&D Process
Organizations can introduce decentralized elements by evaluating how each activity aligns with patient needs, protocol goals, and regulatory expectations.
- Use structured decision frameworks: Existing frameworks can help your team determine which decentralized components make sense to implement for specific studies.
- Engage with regulators early: FDA guidance emphasizes the value of early consultation to align on technology choices, remote oversight strategies, and risk mitigation plans.
- Invest in technology and data reliability: Build systems that support secure data movement, validated digital endpoints, and consistent device configuration.
- Center the patient experience: Test digital tools with real users, simplify instructions, and offer technical support to minimize participant frustration.
- Modernize monitoring approaches: Remote‑friendly trials benefit from risk‑based monitoring and centralized analytics that quickly flag issues at the patient or site level.
- Strengthen vendor and partner ecosystems: Home‑health providers, device suppliers, and data vendors play significant roles in decentralized execution. Strong contracts and clear expectations support quality and compliance.
Insight Global Can Be Your Partner for Progress
As global regulators sharpen guidance and life sciences innovation accelerates, DCTs are positioned to become a cornerstone of next‑generation drug development. But successful implementation requires talent and expertise to scale decentralized models.
As a trusted Functional Service Provider (FSP), Insight Global can build high‑performing clinical operations teams, support decentralized trial execution, strengthen regulatory compliance, and enable digital transformation across the R&D lifecycle.
Whether you’re piloting your first decentralized trial or scaling your process, Insight Global can help you turn innovation into measurable results. Contact us to start a future-focused partnership.
Find Life Sciences Solutions
Questions? Call us toll-free: 855-485-8853
